Macerich (MAC) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Macerich (MAC) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Macerich (MAC) Q3 FFO Lag Estimates
Macerich (MAC) came out with quarterly funds from operations (FFO) of $0.38 per share, missing the Zacks Consensus Estimate of $0.40 per share. This compares to FFO of $0.44 per share a year ago.
Macerich (MAC) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Macerich (MAC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions
The pricing announcement from the Center for Medicare Services became effective on October 1, 2024, and allows BioStem to begin marketing initiatives with Venture Medical POMPANO BEACH, Fla., October 29, 2024 – PRISM MediaWire – BioStem Technologies Inc.
Macerich: Old Retail Is Fading
Macerich is a REIT focused on malls and shopping centers, currently yielding 3.8%, with no clear growth story. Management aims to reduce debt by $2B through asset sales, but this likely means revenue and cash flows will decline in the near term. E-commerce growth and the shift from brick-and-mortar retail present significant challenges, making MAC's turnaround and profitable growth uncertain.
Why Is Macerich (MAC) Up 0.8% Since Last Earnings Report?
Macerich (MAC) reported earnings 30 days ago. What's next for the stock?
Macerich (MAC) Q2 FFO Surpasses Estimates, Revenues Miss
Macerich's (MAC) Q2 results reflect an increase in same-center net operating income. The company also continues with its portfolio quality refining and balance sheet improving efforts.
Macerich: Probability Of Better Dividends Is Weak
MAC reported FFO numbers for its second quarter that dipped 1 cent per share year-over-year. The dividend is 230% covered by FFO but still sits almost 80% below its pre-pandemic level. Management has not made it clear that their path forward plan intends to boost the capacity for more substantial dividend payouts.
Macerich: Solid Progress, But Leverage Remains A Concern
Macerich Company delivered solid Q2, 2024 quarter, especially when it comes to the deleveraging front. The asset disposals so far (including those which are under negotiations) explain already 50% of the $2 billion debt recution target. The business performance was relatively solid, where the FFO per share dropped only by $0.01, which could be viewed positively given the multiple pressures.
Compared to Estimates, Macerich (MAC) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Macerich (MAC) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Macerich (MAC) Q2 FFO Top Estimates
Macerich (MAC) came out with quarterly funds from operations (FFO) of $0.44 per share, beating the Zacks Consensus Estimate of $0.40 per share. This compares to FFO of $0.40 per share a year ago.
Why Is Macerich (MAC) Up 7.6% Since Last Earnings Report?
Macerich (MAC) reported earnings 30 days ago. What's next for the stock?
